Upside for Cosmo, Grossing $89M in Santarus Stock Sale

Cosmo Pharmaceuticals SpA landed a hefty chunk of upside, that all-too-elusive commodity, by grossing $89.2 million from a sale of Santarus Inc. stock. The transaction will enable the already-profitable company to begin paying dividends to its shareholders.

To continue reading subscribe now to BioWorld Asia (formerly International)